The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics’ drug for a type of eye disease, the company said on Tuesday, sending its shares plunging… Reuters Health Information
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete…
When Hearing Fails, Vision Rehab Falls Short
Patients with hearing impairment who receive vision rehabilitation are 42% less likely than those with normal hearing to achieve a meaningful functional improvement, a recent study shows. Medscape Medical News
Uncategorized
FDA’s move away from animal testing is ‘scientifically necessary’
The FDA’s recent announcement to reduce, and in some cases replace, animal testing for monoclonal antibodies and other therapeutics represents one of the most consequential regulatory developments in drug development in decades.If implemented effective…
Change Healthcare Breach Still Affecting Docs, Hospitals
Physicians and hospitals alike are still digging out financially from the impact of the massive Change Healthcare hack in 2024. Medscape Medical News
Motor Impairments Tied to Dementia Risk
Impairments in vision and motor functions are linked to an increased risk of developing dementia among older adults. Medscape Medical News